ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
British Society for Sexual Medicine Guidelines on Male Adult TD
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 248090" data-attributes="member: 13851"><p><strong>The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, With Statements for Practice (2023)</strong></p><p><em>Geoffrey Hackett, Michael Kirby, Rowland W. Rees, T. Hugh Jones, Asif Muneer, Mark Livingston, Nick Ossei-Gerning, Janine David, Jeff Foster, Philip A. Kalra, Sudarshan Ramachandran</em></p><p><em></em></p><p><em></em></p><p><em>Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. <strong>A multi-disciplinary panel from BSSM reviewed the available literature on TD and provide evidence-based statements for clinical practice. </strong>Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testosterone therapy (T Therapy), and cardiovascular safety from May 2017 to September 2022. This revealed 1,714 articles, including 52 clinical trials and 32 placebo-controlled randomized controlled trials. <strong>A total of twenty-five statements are provided, relating to five key areas: screening, diagnosis, initiating T Therapy, benefits and risks of T Therapy, and follow-up. Seven statements are supported by level 1 evidence, eight by level 2, five by level 3, and five by level 4.</strong> Recent studies have demonstrated that low levels of testosterone in men are associated with an increased risk of incident type 2 diabetes mellitus, worse outcomes in chronic kidney disease, and COVID-19 infection with increased all-cause mortality, along with significant quality of life implications. <strong>These guidelines should help practitioners effectively diagnose and manage primary and age-related TD.</strong></em></p><p></p><p></p><p></p><p></p><p><strong>INTRODUCTION</strong><em><strong> </strong></em></p><p><em><strong></strong></em></p><p><em><strong>Testosterone is the principal androgen in men. The term ‘testosterone deficiency (TD)’ is used throughout, in preference to hypogonadism, which refers to under activity of both the endocrine and reproductive function of the testes. TD is a well-established and significant medical condition [1,2]. Testosterone is essential for the development and maintenance of secondary male characteristics [3]. When testosterone levels fall, patients may experience physical, psychological, and metabolic effects, which can compromise their cardiovascular, metabolic, and general health, well-being, sexuality, and fertility [4,5].</strong></em></p><p><em><strong></strong></em></p><p><em><strong>These statements have been developed for <u>UK practice</u> and aim to address the widespread media and scientific concerns over the appropriate treatment of men with TD with testosterone therapy (T Therapy).</strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong>*DEFINITION AND TERMINOLOGY </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*EPIDEMIOLOGY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*BASIC PHYSIOLOGY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*AETIOLOGY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*SUBCLINICAL (COMPENSATED) TD (HYPOGONADISM)</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*PRESCRIBED OPIATE MEDICATIONS </strong></em></p><p></p><p><strong><em>*POST FINASTERIDE SYNDROME </em></strong></p><p></p><p></p><p></p><p></p><p></p><p><em><strong>*CLINICAL DIAGNOSIS OF TD </strong></em></p><p></p><p><strong><em>*SIGNS, SYMPTOMS, AND COMORBIDITIES</em></strong></p><p></p><p></p><p></p><p></p><p><em><strong>*LIFESTYLE CHANGE AND TESTOSTERONE LEVELS</strong></em></p><p></p><p><strong><em>*ORAL SUPPLEMENTS</em></strong></p><p></p><p></p><p></p><p></p><p></p><p><em><strong>*THE RATIONALE FOR T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*TESTOSTERONE AND FERTILITY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*THE BENEFITS OF T THERAPY IN MEN WITH TD</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*POSSIBLE INCREASED CARDIOVASCULAR RISK WITH T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*STUDIES SUGGESTING DECREASED CARDIOVASCULAR RISK WITH T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*FINDINGS FROM META-ANALYSES</strong></em></p><p></p><p><strong><em>*T THERAPY AND RISK OF PCA</em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em>*ROUTINE MEASUREMENT OF TESTOSTERONE</em></strong></p><p><strong><em></em></strong></p><p><strong><em>*HISTORY TAKING AND QUESTIONNAIRES</em></strong></p><p><strong><em></em></strong></p><p><strong><em>*PHYSICAL EXAMINATION</em></strong></p><p><strong><em></em></strong></p><p><strong><em>*DIGITAL RECTAL EXAMINATION </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*LABORATORY DIAGNOSIS</em></strong></p><p></p><p><em><strong>*THRESHOLDS FOR T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong>*TESTOSTERONE THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*THE IMPORTANCE OF CO-ADMINISTRATION OF DAILY PDE5 INHIBITORS IN HYPOGONADISM</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*ALTERNATIVES FOR MEN WITH HYPOGONADISM WHO DESIRE FUTURE FERTILITY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*CARDIOVASCULAR RISK AND TESTOSTERONE THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*ADVERSE EFFECTS OF T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*CONTRAINDICATIONS TO T THERAPY</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*FOLLOW-UP AND MONITORING </strong></em></p><p><em><strong></strong></em></p><p><em><strong>*BSSM POSITION STATEMENT ON COVID-19 INFECTION</strong></em></p><p></p><p></p><p></p><p></p><p><strong>CONCLUSION </strong></p><p></p><p><em><strong>TD is a well-established and significant medical condition, encompassing <u>somatic, sexual, and psychological effects</u>. <u>It is also associated with an increased risk of type 2 diabetes and cardiovascular and all-cause mortality</u>. Clearly defined clinical symptoms, especially ED, loss of morning erections, and reduced sexual desire should prompt swift evaluation of these, together with modification of underlying risk factors, and further investigations performed where appropriate.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>In order to identify individuals who should be screened for TD, consideration should be given to routinely asking men if they have any sexual concerns, particularly those at high risk. These include men with diabetes, osteoporosis/fragility fractures, CVD, CKD, anemia, ED, depression, COVID-19 infection, and those on long-term opiate/oral glucocorticoid therapy</strong></em></p><p><em><strong></strong></em></p><p><em><strong><u>T Therapy is evidence-based, effective, and safe, and evidence suggests that treatment-related sustained normalization of serum testosterone levels is associated with reduced morbidity and mortality</u>.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>However, whilst the multiple benefits of T Therapy are highly relevant to the patient, they are often underestimated by specialist physicians focused on specific outcomes related to their particular discipline. <u>Because sexual dysfunction is often multi-faceted in nature, the treatment of men with sexual desire, arousal, and ejaculation problems should be individualized and may include T Therapy, erectogenic agents, and psychosexual therapy</u>.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>Until a definitive well-powered long-term study is published, the <u>treatment of TD with T Therapy should be guided by the best available evidence</u>.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 248090, member: 13851"] [B]The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, With Statements for Practice (2023)[/B] [I]Geoffrey Hackett, Michael Kirby, Rowland W. Rees, T. Hugh Jones, Asif Muneer, Mark Livingston, Nick Ossei-Gerning, Janine David, Jeff Foster, Philip A. Kalra, Sudarshan Ramachandran Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. [B]A multi-disciplinary panel from BSSM reviewed the available literature on TD and provide evidence-based statements for clinical practice. [/B]Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testosterone therapy (T Therapy), and cardiovascular safety from May 2017 to September 2022. This revealed 1,714 articles, including 52 clinical trials and 32 placebo-controlled randomized controlled trials. [B]A total of twenty-five statements are provided, relating to five key areas: screening, diagnosis, initiating T Therapy, benefits and risks of T Therapy, and follow-up. Seven statements are supported by level 1 evidence, eight by level 2, five by level 3, and five by level 4.[/B] Recent studies have demonstrated that low levels of testosterone in men are associated with an increased risk of incident type 2 diabetes mellitus, worse outcomes in chronic kidney disease, and COVID-19 infection with increased all-cause mortality, along with significant quality of life implications. [B]These guidelines should help practitioners effectively diagnose and manage primary and age-related TD.[/B][/I] [B]INTRODUCTION[/B][I][B] Testosterone is the principal androgen in men. The term ‘testosterone deficiency (TD)’ is used throughout, in preference to hypogonadism, which refers to under activity of both the endocrine and reproductive function of the testes. TD is a well-established and significant medical condition [1,2]. Testosterone is essential for the development and maintenance of secondary male characteristics [3]. When testosterone levels fall, patients may experience physical, psychological, and metabolic effects, which can compromise their cardiovascular, metabolic, and general health, well-being, sexuality, and fertility [4,5]. These statements have been developed for [U]UK practice[/U] and aim to address the widespread media and scientific concerns over the appropriate treatment of men with TD with testosterone therapy (T Therapy). *DEFINITION AND TERMINOLOGY *EPIDEMIOLOGY *BASIC PHYSIOLOGY *AETIOLOGY *SUBCLINICAL (COMPENSATED) TD (HYPOGONADISM) *PRESCRIBED OPIATE MEDICATIONS [/B][/I] [B][I]*POST FINASTERIDE SYNDROME [/I][/B] [I][B]*CLINICAL DIAGNOSIS OF TD [/B][/I] [B][I]*SIGNS, SYMPTOMS, AND COMORBIDITIES[/I][/B] [I][B]*LIFESTYLE CHANGE AND TESTOSTERONE LEVELS[/B][/I] [B][I]*ORAL SUPPLEMENTS[/I][/B] [I][B]*THE RATIONALE FOR T THERAPY *TESTOSTERONE AND FERTILITY *THE BENEFITS OF T THERAPY IN MEN WITH TD *POSSIBLE INCREASED CARDIOVASCULAR RISK WITH T THERAPY *STUDIES SUGGESTING DECREASED CARDIOVASCULAR RISK WITH T THERAPY *FINDINGS FROM META-ANALYSES[/B][/I] [B][I]*T THERAPY AND RISK OF PCA *ROUTINE MEASUREMENT OF TESTOSTERONE *HISTORY TAKING AND QUESTIONNAIRES *PHYSICAL EXAMINATION *DIGITAL RECTAL EXAMINATION *LABORATORY DIAGNOSIS[/I][/B] [I][B]*THRESHOLDS FOR T THERAPY *TESTOSTERONE THERAPY *THE IMPORTANCE OF CO-ADMINISTRATION OF DAILY PDE5 INHIBITORS IN HYPOGONADISM *ALTERNATIVES FOR MEN WITH HYPOGONADISM WHO DESIRE FUTURE FERTILITY *CARDIOVASCULAR RISK AND TESTOSTERONE THERAPY *ADVERSE EFFECTS OF T THERAPY *CONTRAINDICATIONS TO T THERAPY *FOLLOW-UP AND MONITORING *BSSM POSITION STATEMENT ON COVID-19 INFECTION[/B][/I] [B]CONCLUSION [/B] [I][B]TD is a well-established and significant medical condition, encompassing [U]somatic, sexual, and psychological effects[/U]. [U]It is also associated with an increased risk of type 2 diabetes and cardiovascular and all-cause mortality[/U]. Clearly defined clinical symptoms, especially ED, loss of morning erections, and reduced sexual desire should prompt swift evaluation of these, together with modification of underlying risk factors, and further investigations performed where appropriate. In order to identify individuals who should be screened for TD, consideration should be given to routinely asking men if they have any sexual concerns, particularly those at high risk. These include men with diabetes, osteoporosis/fragility fractures, CVD, CKD, anemia, ED, depression, COVID-19 infection, and those on long-term opiate/oral glucocorticoid therapy [U]T Therapy is evidence-based, effective, and safe, and evidence suggests that treatment-related sustained normalization of serum testosterone levels is associated with reduced morbidity and mortality[/U]. However, whilst the multiple benefits of T Therapy are highly relevant to the patient, they are often underestimated by specialist physicians focused on specific outcomes related to their particular discipline. [U]Because sexual dysfunction is often multi-faceted in nature, the treatment of men with sexual desire, arousal, and ejaculation problems should be individualized and may include T Therapy, erectogenic agents, and psychosexual therapy[/U]. Until a definitive well-powered long-term study is published, the [U]treatment of TD with T Therapy should be guided by the best available evidence[/U].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
British Society for Sexual Medicine Guidelines on Male Adult TD
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top